IgE peptide-specific CTL inhibit IgE production: A transient IgE suppression model in wild-type and HLA-A2.1 transgenic mice

Cellular Immunology

Volumn 254, Issue 1, 2008, Pages 28-38

  Chen, Swey Shen ^a,b   Barankiewicz, Teresa J ^a,b   Yang, Yong Min ^a,b   Goebel, Peter ^a,b   Liu, Fu Tong ^c  

^a The Institute of Genetics   (United States)

^b IgE Therapeutics Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CpG; Natural human IgE peptide; Pan IgE peptide human vaccine; Transient IgE suppression

Indexed keywords

CD8 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; PROTEIN PI 1; PWV; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BONE MARROW CELL; CELL CULTURE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SPLEEN CELL; VACCINATION;

ANIMALS; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, SUBUNIT;

MUS; MUS MUSCULUS;

EID: 55149088124     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.06.008     Document Type: Article

References (49)

1. Larche M. Peptide immunotherapy. Immunol. Allergy Clin. North Am. 26 viii (2006) 321-332
2. Amin H.S., Liss G.M., and Bernstein D.I. Evaluation of near-fatal reactions to allergen immunotherapy injections. J. Allergy Clin. Immunol. 117 (2006) 169-175
3. A. Committee, Advisory Committee Clinical Efficacy Briefing Document, Genentech, Inc.: omalizumab for asthma, Biologics Marketing Application STN 103976/0 DHHS, PHS, FDA (2003) 1-118.
4. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 18 (2000) 157-162
5. M. Hitti, L. Chang, Xolair gets 'Black Box' warning, WebMD Medical News (2007) July 3.
6. Cox L., Platts-Mills T.A.E., Finegold I., Schwartz L.B., Simons F.E., and Wallace D.V. American academy of allergy asthma and immunology/american college of allergy and immunology joint task force report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 120 (2007) 1373-1377
7. Wang Y., Schmaltz R., Liu F.T., Robertson M.W., Petro T.M., and Chen S.S. Peptides derived from IgE heavy chain constant region induce profound IgE isotype-specific tolerance. Eur. J. Immunol. 26 (1996) 1043-1049
8. Wang Y.-Y., Li Q., Schmaltz R., Chen W.-H., and Chen S.-S. Inhibition of IgE responses with monoclonal anti-IgE and IgE peptide-protein conjugates in vitro and in vivo. FASEB J. 9 (1995) 4645
9. Chen S.-S., Gong J., Liu F.-T., Goebel P., Oettgen H., and Zanetti M. Cytotoxic T-cells specific for natural IgE peptides downregulate IgE production. Cell. Immunol. 233 (2005) 11-25
10. Chen S.S. What determines an antigen-specific IgE isotypic response? a hypothesis [editorial]. Scand. J. Immunol. 34 (1991) 519-529
11. Chen S.S. Mechanisms of IgE tolerance: dual regulatory T cell lesions in perinatal IgE tolerance. Eur. J. Immunol. 21 (1991) 2461-2467
12. Chen S.S. Genesis of host IgE competence: perinatal IgE tolerance induced by IgE processed and presented by IgE Fc receptor (CD23)-bearing B cells. Eur. J. Immunol. 22 (1992) 343-348
13. Chen S.-S., Wang Y.-Y., Schmaltz R., Qian Y.-Y., and Liu F.-T. Two-signal deterministic theory of IgE production re-visited: Evidence for the pivotal regulatory IgE peptide sequences from the IgE constant region. FASEB J. 9 (1995) 802A-8020
14. Chen S.S., Schmaltz R., Wang Y.Y., Kong Q.X., Petro T., Li Q., and Chang T.W. Inhibition of antigen-specific IgE production by antigen coupled to membrane IgE peptide. Immunol. Invest. 25 (1996) 495-505
15. Minev B., Hipp J., Firat H., Schmidt J.D., Langlade-Demoyen P., and Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 97 (2000) 4796-4801
16. Hernandez J., Garcia_Pons F., Lone Y.C., Firat H., Schmidt J.D., Langlade_Demoyen P., and Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. USA 99 (2002) 12275-12280
17. Vitiello A., Marchesini D., Furze J., Sherman L.A., and Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173 (1991) 1007-1015
18. S.-S. Chen, M. Hatlen, T.J. Barankiewicz, Natural human IgE peptide-specific CTL inhibit human IgE production and eliminate U266 in HLA-A2 transgenic rodents, FASEB J, 2008, in press.
19. Chen S.-S., Liu F.-T., and Katz D.H. Cellular and molecular mechanisms of murine IgE class-restricted tolerance induced by neonatal administration of soluble or cell-bound IgE. J. Exp. Med. 160 (1984) 953-970
20. Chen S.S. Enumeration of antigen-specific IgE responses at the single-cell level by an ELISA plaque assay. J. Immunol. Meth. 135 (1990) 129-138
21. Liu F., Bohn J., Ferry E., Yamamoto H., Molinaro C., Sherman L., Klinman N., and Katz D. Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization. J. Immunol. 124 (1980) 2728-2737
22. Yoshizawa K., and Yano A. Mouse T lymphocytes proliferative responses specific for human MHC products in mouse anti-human xenogeneic MLR. J. Immunol. 132 (1984) 2820-2829
23. Kaplan E.L., and Meier P. Nonparametric estimation of incomplete observations. J. American Stat. Asso. 53 (1958) 457-481
24. Townsend A., Ohlen C., Foster L., Bastin J., Ljunggren H.G., and Karre K. A mutant cell in which association of class I heavy and light chains is induced by viral peptides. Cold Spring Harbor Symposium. Quant. Biol. 54 Pt. 1 (1989) 299-308
25. Sherman L.A., Hesse S.V., Irwin M.J., La_Face D., and Peterson P. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258 (1992) 815-818
26. Lauritzsen G.F., Weiss S., Dembic Z., and Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Natl. Acad. Sci. USA 91 (1994) 5700-5704
27. Walden P., Nagy Z.A., and Klein J. Antigen presentation by liposomes: inhibition with antibodies. Eur. J. Immunol. 16 (1986) 717-720
28. Chen S.-S., and Katz D.H. IgE class-restricted tolerance induced by neonatal administration of soluble or cell-bound IgE. J. Exp. Med. 57 (1983) 772-788
29. Badovinac V.P., Messingham K.A., Jabbari A., Haring J.S., and Harty J.T. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11 (2005) 748-756
30. Schmaltz R., Wang Y.Y., Kung Q.X., Liu F.-T., Petro T., and Chen S.-S. B cell hybridoma presents both B-cell and T-cell epitopes for stimulating antibody production via CD23 pathway. Immunol. Inves. 25 (1996) 481-493
31. Mcheyzer-Williams L.J., Cool M., and Mcheyzer-Williams M.G. Antigen-specific B cell memory: Expression and replenishment of a novel B220- memory B cell compartment. J. Exp. Med. 191 (2000) 1149-1166
32. Karagiannis S.N., Wang Q., East N., Burke F., Riffard S., Bracher M.G., Thompson R.G., Durham S.R., Schwartz L.B., Balkwill F.R., and Gould H.J. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 33 (2003) 1030-1040
33. Lindelof B., Granath F., Tengvall-Linder M., and Ekbom A. Allergy and cancer. Allergy 60 (2005) 1116-1120
34. Wang H., and Diepgen T.L. Is atopy a protective or a risk factor for cancer? a review of epidemiological studies. Allergy 60 (2005) 1098-1111
35. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., and Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18 (2000) 509-514
36. Gierynska M., Kumaraguru U., Eo S.-K., Lee S., Krieg A., and Rouse B.T. Induction of CD8 T-Cell-specific systemic and mucosal immunity against Herpes Simplex Virus with CpG-peptide complexes. J. Virol. 76 (2002) 6568-6576
37. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., and Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003) 852-856
38. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 (2003) 339-342
39. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T Cell Memory. Science 300 (2003) 337-339
40. Bevan M.J. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4 (2004) 595-602
41. Heit A., Schmitz F., O'Keeffe M., Staib C., Busch D.H., Wagner H., and Huster K.M. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174 (2005) 4373-4380
42. Gray R.C., Kuchtey J., and Harding C.V. CpG-B ODNs potently induce low levels of IFN-a/b and induce IFN-a/b-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J. Leukoc. Biol. 81 (2007) 1075-1085
43. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG Oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) Immunity. J. Exp. Med. 186 (1997) 1623-1631
44. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., Kagey-Sobotka A., Creticos P.S., Lichtenstein L.M., Spiegelberg H.L., and Raz E. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106 (2000) 124-134
45. Hogan R.J., Usherwood E.J., Zhong W., Roberts A.D., Dutton R.W., Harmsen A.G., and Woodland D.L. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166 (2001) 1813-1822
46. Masopust D., Vezys V., Marzo A.L., and Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291 (2001) 2413-2417
47. Kulczycki A., Isersky C., and Metzger H. The interaction of IgE with rat basophilic leukemia cells. I. Evidence for specific binding of IgE. J. Exp. Med. 139 (1974) 600-616
48. MacGlashan D.W., Bochner B.S., Adelman D.G., Jardieu P.M., Togias A., McKenzie-White J., Sterbinsky S.A., Hamilton R.G., and Lichtenstein L.M. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158 (1997) 1438-1445
49. Chang T.W., and Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J. Allergy Clin. Immunol. 117 (2006) 1203-1212